Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 14/20 | 0.41 |
| ▸ | KDR | P35968 | 13/20 | 0.41 |
| ▸ | RAF1 | P04049 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24374434 | 0.87 | ABL1 (0.54) | BRAFKDRRAF1ABL1BCR | |
| SCHEMBL24374953 | 0.84 | BRAF (0.52) | BRAFKDRRAF1ABL1BCR | |
| SCHEMBL24374954 | 0.79 | BRAF (0.60) | BRAFKDRRAF1ABL1BCR | |
| SCHEMBL24374441 | 0.76 | ABL1 (0.54) | BRAFKDRRAF1ABL1BCR | |
| SCHEMBL25592309 | 0.75 | MAPK14 (0.45) | BRAFKDRCSF1RPDGFRBPDGFRA | |
| SCHEMBL24374435 | 0.75 | MAPK14 (0.45) | BRAFKDRCSF1RPDGFRBPDGFRA | |
| SCHEMBL24374458 | 0.72 | ABL1 (0.55) | BRAFKDRRAF1ABL1BCR | |
| SCHEMBL24813423 | 0.72 | KDR (0.52) | BRAFKDR | |
| SCHEMBL23795595 | 0.71 | ABL1 (0.54) | BRAFKDRRAF1ABL1BCR | |
| SCHEMBL24007131 | 0.70 | BRAF (0.49) | BRAFKDRRAF1ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183204-A9 | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20220127246-A1 | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127246-A1 | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | BRAF 87/4885KDR 260/4885RAF1 803/4885 |
| US-20230183204-A9 | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | BRAF 87/4885KDR 260/4885RAF1 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.